Prospective multicenter assessment of patient preferences for properties of gadolinium-based contrast media and their potential socioeconomic impact in a screening breast MRI setting

• Type of Material: Article
• Authors: Sean A. Woolen, University of California San Francisco; Jonathan P. Troost, Michigan Medicine; Shokoufeh Khalatbari, Michigan Medicine; Akshat Pujara, Emory University; Jennifer S. McDonald, Mayo Clinic; Robert J. McDonald, Mayo Clinic; Prasad Shankar, Michigan Medicine; Alana A. Lewin, New York University; Amy N. Melsaether, Mt Sinai; Steven M. Westphal, Indiana University; Katherine H. Patterson, Indiana University; Ashley Nettles, Michigan Medicine; John P. Welby, Mayo Clinic; Parth Pradip Patel, Mayo Clinic; Neud Kiros, Indiana University; Lisa Piccoli, New York University; Matthew S. Davenport, Michigan Medicine
• Language: English
• Date: 2021-05-28
• Publisher: SPRINGER
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2021
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1007/s00330-021-07982-y
• Title of Journal or Parent Work: EUROPEAN RADIOLOGY
• Volume: 31
• Issue: 12
• Start Page: 9139
• End Page: 9149
• Grant/Funding Information: This study was supported by the National Center for Advancing Translational Sciences (NCATS Grant Number: UL1TR002240) for the Michigan Institute for Clinical and Health Research.
• Keywords: RACE; Science & Technology; Life Sciences & Biomedicine; DEPOSITION; DISPARITIES; AGENTS; BRAIN; Mass screening; INCOME; Magnetic resonance imaging; RETENTION; Patient-centered care; Gadolinium; Radiology, Nuclear Medicine & Medical Imaging; Contrast media; MORTALITY; TISSUE
• Research Categories: Sociology, Social Structure and Development; Health Sciences, Radiology; Health Sciences, Health Care Management

Abstract

Objective: It is unknown how patients prioritize gadolinium-based contrast media (GBCM) benefits (detection sensitivity) and risks (reactions, gadolinium retention, cost). The purpose of this study is to measure preferences for properties of GBCM in women at intermediate or high risk of breast cancer undergoing annual screening MRI. Methods: An institutional reviewed board-approved prospective discrete choice conjoint survey was administered to patients at intermediate or high risk for breast cancer undergoing screening MRI at 4 institutions (July 2018–March 2020). Participants were given 15 tasks and asked to choose which of two hypothetical GBCM they would prefer. GBCMs varied by the following attributes: sensitivity for cancer detection (80–95%), intracranial gadolinium retention (1–100 molecules per 100 million administered), severe allergic-like reaction rate (1–19 per 100,000 administrations), mild allergic-like reaction rate (10–1000 per 100,000 administrations), out-of-pocket cost ($25–$100). Attribute levels were based on published values of existing GBCMs. Hierarchical Bayesian analysis was used to derive attribute “importance.” Preference shares were determined by simulation. Results: Response (87% [247/284]) and completion (96% [236/247]) rates were excellent. Sensitivity (importance = 44.3%, 95% confidence interval = 42.0–46.7%) was valued more than GBCM-related risks (mild allergic-like reaction risk (19.5%, 17.9–21.1%), severe allergic-like reaction risk (17.0%, 15.8–18.1%), intracranial gadolinium retention (11.6%, 10.5–12.7%), out-of-pocket expense (7.5%, 6.8–8.3%)). Lower income participants placed more importance on cost and less on sensitivity (p < 0.01). A simulator is provided that models GBCM preference shares by GBCM attributes and competition. Conclusions: Patients at intermediate or high risk for breast cancer undergoing MRI screening prioritize cancer detection over GBCM-related risks, and prioritize reaction risks over gadolinium retention. Key Points: • Among women undergoing annual breast MRI screening, cancer detection sensitivity (attribute “importance,” 44.3%) was valued more than GBCM-related risks (mild allergic reaction risk 19.5%, severe allergic reaction risk 17.0%, intracranial gadolinium retention 11.6%, out-of-pocket expense 7.5%). • Prospective four-center patient preference data have been incorporated into a GBCM choice simulator that allows users to input GBCM properties and calculate patient preference shares for competitor GBCMs. • Lower-income women placed more importance on out-of-pocket cost and less importance on cancer detection (p < 0.01) when prioritizing GBCM properties.